111 - 120 of 4301 Drugs
Aczone Gel (dapsone)
Aczone (dapsone) Gel, 5% is a sulfone drug indicated for the topical treatment of acne vulgaris. Aczone Gel 5% is available in generic form.
Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed)
Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) is a "booster" vaccine given to maintain protection (immunity) against diphtheria, tetanus (lockjaw), and pertussis (whooping cough) in children and adults aged 11 to 64 years who have been vaccinated for these diseases in the past.
Adagen (pegademase bovine)
Adagen (pegademase bovine) Injection is an enzyme called adenosine deaminase (ADA) used for enzyme replacement therapy for the treatment of severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase.
Krazati (adagrasib tablets)
Krazati (adagrasib) is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
Adakveo (crizanlizumab-tmca injection)
Adakveo (crizanlizumab-tmca) is a selectin blocker used to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Adalat CC (nifedipine)
Adalat (nifedipine) is a calcium channel blocker drug that relaxes (widens) blood vessels (veins and arteries), which makes it easier for the heart to pump and reduces its workload and is used to lower high blood pressure (hypertension) and to treat chest pain (angina).
Humira (adalimumab injection solution for subcutaneous administration)
Humira (adalimumab) is an injectable protein (antibody) used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Humira is also used to treat Crohn's disease after other drugs have been tried without successful treatment of symptoms.
Idacio (adalimumab-aacf injection)
Idacio (adalimumab-aacf) is a tumor necrosis factor (TNF) blocker indicated for reducing signs and symptoms of rheumatoid arthritis (RA), inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA; reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 2 years of age and older; reducing signs and symptoms of psoriatic arthritis (PsA), inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA; reducing signs and symptoms of ankylosing spondylitis (AS) in adult patients with active AS; treatment of moderately to severely active Crohn’s disease (CD) in adults and pediatric patients 6 years of age and older; treatment of moderately to severely active ulcerative colitis (UC) in adult patients; and for treatment of adult patients with moderate to severe chronic plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
Yuflyma (adalimumab-aaty injection)
Yuflyma (adalimumab-aaty) is a tumor necrosis factor (TNF) blocker indicated for: reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA); reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 2 years of age and older; reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis (PsA); reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS); treatment of moderately to severely active Crohn’s disease(CD) in adults and pediatric patients 6 years of age and older; treatment of moderately to severely active ulcerative colitis (UC) in adult patients; treatment of adult patients with moderate to severe chronic plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate; and treatment of moderate to severe hidradenitis suppurativa (HS) in adult patients.